Swedish Orphan Biovitrum AB (Sobi)(STO:SOBI), a speciality healthcare company dedicated to rare diseases, on Thursday reported profit of SEK1,149m, or EPS of SEK4.27, for the full year 2017.

This was a 43% increase over profit of SEK802m, or EPS of SEK2.99, in 2016.

Total revenues for the full-year amounted to SEK6,511m, up by 25% as compared with SEK5,204m in 2016. The increase was 24% at constant exchange rates.

Product sales for the full-year amounted to SEK5,917m, up by 30% over SEK4,548m in 2016.

Also, the company's board of directors has proposed that no dividend be paid for the 2017.

In addition, the company provided outlook for 2018 and expects total revenues for the full-year to be in the range of SEK7,500m to SEK7,700m.

Sobi's product portfolio is primarily focused on treatments in Haemophilia and Specialty Care.

(EUR1.00=SEK10.00)